Appendix 4D

Half Year Report to the Australian Stock Exchange

Name of Entity	BTC health Limited
ABN	45 091 979 172
Half Year Ended	31 December 2019
Previous Corresponding	31 December 2018
Reporting Period	

Results for Announcement to the Market

	31/12/2019 \$'000	31/12/2018 \$'000	Percentage increase / (decrease) over previous corresponding period
Revenue from ordinary activities	182	105	73.33%
Profit / (loss) from ordinary activities after tax attributable to members	(221)	(246)	10.16%
Net profit / (loss) for the period attributable to members	(221)	(246)	10.16%

Dividends	Amount per securit	y Franked amount per
(distributions)	-	security
Dividend 31/12/19	Nil	Nil
Interim Dividend	Nil	Nil
Record date for determin	ing entitlements	
to the dividends (if any)	N/A	

Brief explanation of any of the figures reported above necessary to enable the figures to be understood:

The company made a loss after tax during the half-year of \$221,288 (2018: \$245,587). The decreased loss was due to the revaluation of Bio101 and increased Management Fee income, partially offset by timing of expenses incurred.

Dividends

Date the dividend is payable	N/A
Record date to determine	
entitlement to the dividend	N/A
Amount per security	N/A
Total dividend	N/A
Amount per security of foreign	
sourced dividend or distribution	N/A
Details of any dividend reinvestment	
plans in operation	N/A
The last date for receipt of an	
election notice for participation in	
any dividend reinvestment plans	N/A

NTA Backing

	Current Period	Previous corresponding period
Net tangible asset backing per ordinary security	4.59 cents	2.11 cents

Control Gained Over Entities Having Material Effect

	-
Name of entity (or group of entities)	None
Date control gained	N/A
Consolidated profit / (loss) from	N/A
ordinary activities since the date in the	
current period on which control was	
acquired	
Profit / (loss) from ordinary activities of	N/A
the controlled entity (or group of	
entities) for the whole of the previous	
corresponding period	

Loss of Control Gained Over Entities Having Material Effect

Name of entity (or group of entities)	None
Date control lost	N/A
Consolidated profit / (loss) from	N/A
ordinary activities for the current period	
to the date of loss of control	
Profit / (loss) from ordinary activities of	N/A
the controlled entity (or group of	
entities) while controlled for the whole	
of the previous corresponding period	

Details of Associates and Joint Venture Entities

Name of Entity	Percentage Held		Share of Net Profit	
	Current Period	Previous Period	Current Period	Previous Period
None	N/A	N/A	N/A	N/A
Aggregate Share of Net Profits	N/A	N/A	N/A	N/A

Foreign E	Entities	Accounting	Framework
-----------	----------	------------	------------------

r orongin Emilioo 7 tooodiniing r ramowork
For foreign entities provide details of which accounting standards have been adopted (e.g. International Accounting Standards)
N/A

Audit/Review Status

This report is based on accounts to which one of the following applies: (Tick one)				
The accounts have been audited				
If the accounts are subject to audit dispute or qualification, a description of the dispute or qualification:				

Attachments Forming Part of Appendix 4D

Attachments I chining I art of Appendix 45		
Attachment #	Details	
1	Interim Financial Report	
Signed by Com	pany Secretary	SISC
Print Name		Sharon Papworth
Date		18 February 2020

ABN 45 091 979 172

HALF-YEAR FINANCIAL REPORT FOR THE HALF-YEAR ENDED 31 DECEMBER 2019

CONTENTS

CORPORATE DIRECTORY	.3
DIRECTORS' REPORT	.4
AUDITOR'S INDEPENDENCE DECLARATION	.5
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME	
STATEMENT OF FINANCIAL POSITION	.7
STATEMENT OF CASH FLOWS	.8
STATEMENT OF CHANGES IN EQUITY	9
NOTES TO THE FINANCIAL STATEMENTS1	10
DIRECTORS' DECLARATION1	16
INDEPENDENT AUDITOR'S REVIEW REPORT	17

CORPORATE DIRECTORY

Principal and registered office in BTC health Limited

Australia Suite 201 / 697 Burke Road

Camberwell VIC 3124 T +61 3 9092 0470

Directors Richard Treagus

Jonathan Pilcher Bruce Hewett

Peter Jones (resigned 26 November 2019)

Company Secretary Sharon Papworth

Bankers Westpac Banking Corporation

Share Register Link Market Services

Tower 4, 727 Collins Street MELBOURNE VIC 3008

Locked Bag A14

SYDNEY SOUTH NSW 1235

T 1300 554 474 F (02) 9287 0303

Auditor Grant Thornton

Collins Square, Tower 5 727 Collins Street MELBOURNE VIC 3008

Internet Address www.btchealth.com.au

HALF-YEAR FINANCIAL REPORT

DIRECTORS' REPORT

Your directors submit the financial report of the company for the half-year ended 31 December 2019.

Directors

Richard Treagus Jonathan Pilcher Bruce Hewett

Review of Operations

The following is a review of operations for the six-month period to 31 December 2019:

The company made a loss after tax during the half-year of \$221,288 (Dec 2018: \$245,587). Revenue of \$111,611 (Dec 2018: \$105,218) largely comprises Management Fees and the revaluation of Bio101group. Expenses for the half-year were \$402,899 (Dec 2018: \$350,805) and reflect running costs of the company. Cash balances at 31 December 2019 were \$3,392,921 (June 2019: \$3,942,921).

The hospital infusion business that was acquired on 31 May 2019 has been integrated within BTC Speciality Health. Sales, supply chain and distribution integration is complete. Sales strategies are developed and being deployed into the market.

BTC maintained its existing investments in Bio101group Pty Ltd, BioImpact Pty Ltd, BTC Speciality Health and Sensear Pty Ltd, as well as actively seeking opportunities for new investments in healthcare. BTC health's investment in Bio101group has been revalued up to \$470,000 during the period due to its growth in both revenue and profit.

BTC health is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992.

Subsequent Events


No matters have arisen between the end of the half-year ended 31 December 2019 and the date of this report which in the opinion of the directors of the company, will affect significantly the operations of the entity, the results of those operations, or the state of the affairs of the entity in subsequent financial years.

Auditor's Declaration of Independence

A copy of the auditor's declaration under section 307C in relation to the half year is included on page 5. This report is signed in accordance with a resolution of the Board of Directors made pursuant to s.306(3) of the Corporations Act 2001.

Richard Treagus Executive Chairman

Dated 18th February 2020



Collins Square, Tower 5 727 Collins Street Melbourne VIC 3008

Correspondence to: GPO Box 4736 Melbourne VIC 3001

T +61 3 8320 2222 F +61 3 8320 2200 E <u>info.vic@au.gt.com</u> W www.grantthornton.com.au

Auditor's Independence Declaration

To the Directors of BTC Health Limited

In accordance with the requirements of section 307C of the *Corporations Act 2001*, as lead auditor for the review of BTC Health Limited for the half year ended 31 December 2019, I declare that, to the best of my knowledge and belief, there have been:

- a no contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the review; and
- b no contraventions of any applicable code of professional conduct in relation to the review.

Grant Thornton Audit Pty Ltd Chartered Accountants

M A Cunningham

Partner - Audit & Assurance

Melbourne, 18 February 2020

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE HALF-YEAR ENDED 31 DECEMBER 2019

	31 December 2019 \$	31 December 2018 \$
Revenue	·	·
Interest income	6,611	10,218
Management Fee	80,000	40,000
Increase in fair value of investment (Note 2)	95,000	55,000
	181,611	105,218
Expenses	•	,
Due Diligence costs	-	(52,052)
Executive Director fees	(204,974)	(60,000)
Non-Executive Director fees	(36,860)	(30,000)
Listing fees	(35,753)	(32,132)
Share registry	(13,592)	(10,031)
Share based payments	(9,588)	(28,076)
Insurance	(16,549)	(12,249)
Legal Fees	(1,473)	(31,317)
Audit Fees	(15,000)	(13,125)
Accounting and company secretarial	(46,281)	(33,500)
Other expenses from operations	(22,829)	(48,323)
	(402,899)	(350,805)
Loss before income tax expense	(221,288)	(245,587)
Income tax benefit	-	
Loss for the period	(221,288)	(245,587)
Other comprehensive income	-	-
TOTAL COMPREHENSIVE LOSS FOR THE		
PERIOD	(221,288)	(245,587)
Basic loss per share (cents per share) Diluted loss per share (cents per share)	(0.09) (0.09)	(0.19) (0.19)

The accompanying notes form part of this financial report.

STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2019

	31 December 2019 \$	30 June 2019 \$
CURRENT ASSETS		
Cash and cash equivalents	3,392,921	3,942,921
Trade receivables	43,632	120,743
Other assets	31,902	42,896
TOTAL CURRENT ASSETS	3,468,455	4,106,560
NON CURRENT ASSETS		
Financial assets (Note 2)	6,470,100	6,375,100
Loans to investee companies (Note 3)	1,528,006	1,237,691
TOTAL NON CURRENT ASSETS	7,998,106	7,612,791
TOTAL ASSETS	11,466,561	11,719,351
CURRENT LIABILITIES		
Trade and other payables	47,432	158,493
Unclaimed monies	106,727	219,834
TOTAL CURRENT LIABILITIES	154,159	378,327
TOTAL LIABILITIES	154,159	378,327
NET ASSETS	11,312,402	11,341,024
EQUITY		
Issued capital (Note 4)	53,287,933	53,104,855
Other reserves	295,699	346,914
Accumulated losses	(42,271,230)	(42,110,745)
TOTAL EQUITY	11,312,402	11,341,024
IVIAL EQUIII	11,312,402	11,341,024

The accompanying notes form part of this financial report

STATEMENT OF CASH FLOWS FOR THE HALF-YEAR ENDED 31 DECEMBER 2019

	31 December 2019 \$	31 December 2018 \$
CASH FLOWS FROM OPERATING ACTIVITIES		
Interest received	6,611	10,218
Payments to suppliers and employees	(130,185)	(308,358)
Net cash used in operating activities	(123,574)	(298,140)
CASH FLOWS FROM INVESTING ACTIVITIES		
Loan advanced to investee companies	(290,315)	(272,677)
Net cash used in investing activities	(290,315)	(272,677)
CASH FLOW FROM FINANCING ACTIVITIES	(22.004)	
Share placement costs	(23,004)	(22.040)
Unclaimed monies paid	(113,107)	(32,019)
Net cash used in financing activities	(136,111)	(32,019)
_		
Net decrease in cash and cash equivalents held	(550,000)	(602,836)
Cash and cash equivalents at beginning of the half-year	3,942,921	2,649,629
Cash and cash equivalents at end of half-year	3,392,921	2,046,793

The accompanying notes form part of this financial report

STATEMENT OF CHANGES IN EQUITY FOR THE HALF-YEAR ENDED 31 DECEMBER 2019

	Issued capital	Accumulated Losses	Other reserves	Total
	\$	\$	\$	\$
At 1 July 2018 Loss for the period Other comprehensive income	44,255,057 - -	(41,440,510) (245,587)	158,455 - -	2,973,002 (245,587)
Total comprehensive loss for the period Transactions with owners in their		(245,587)	<u>-</u>	(245,587)
capacity as owners: Share based payments At 31 December 2018	44,255,057	- (41,686,097)	28,076 186,531	28,076 2,755,491
At 1 July 2019 Loss for the period Other comprehensive income	53,104,855 - -	(42,110,745) (221,288)	346,914 - -	11,341,024 (221,288)
Total comprehensive loss for the period Transactions with owners in their capacity as owners:	-	(221,288)	-	(221,288)
Share based payments At 31 December 2019	183,078 53,287,933	60,803 (42,271,230)	(51,215) 295,699	192,666 11,312,402

The accompanying notes form part of this financial report

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2019

Note 1: Significant Accounting Policies

Statement of compliance

The half-year financial report is a general purpose financial report prepared in accordance with the requirements of the *Corporations Act 2001* and AASB 134: Interim Financial Reporting. Compliance with AASB 134 ensures compliance with International Financial Reporting Standards IAS 34 Interim Financial Reporting.

The half-year financial report does not include all notes of the type normally included within the full financial report and therefore cannot be expected to provide as full an understanding of the financial performance, financial position and financing and investing activities of the entity as the full financial report.

It is recommended that this financial report be read in conjunction with the annual financial report for the year ended 30 June 2019 and any announcements made by BTC health Limited during the half-year in accordance with continuous disclosure requirements arising under the *Corporations Act 2001*.

Basis of Preparation

The financial report of BTC health Limited for the half-year ended 31 December 2019 was authorised for issue in accordance with a resolution of the directors on 18 February 2020. BTC health Limited is a company incorporated in Australia and limited by shares which are publicly traded on the Australian Securities Exchange.

The accounting policies have been consistently applied and are consistent with those applied in the 30 June 2019 annual report, except for the adoption of new or revised standards mandatory for annual periods beginning on or after 1 July 2019, as noted below.

The half-year financial report has been prepared on a historical cost basis, except for financial assets that have been measured at fair value. For the purpose of preparing the half-year financial report, the half-year has been treated as a discrete reporting period.

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2019

Note 1: Significant Accounting Policies - Continued

Adoption of new and revised Accounting Standards

a) New and amended Accounting Standards that are effective for the current year

i) AASB 16 - Leases

AASB 16 Leases is effective for annual reporting periods beginning on or after 1 January 2019 and for reporting by the Company in the half-year ended 31 December 219.

The standard will result in almost all leases being recognised on the balance sheet, as the distinction between operating and finance leases has been removed. Under the new standard, an asset (the right to use the leased item) and a financial liability to pay rentals are recognised. The only exceptions are short term and low-value leases. The accounting for lessors will not significantly change.

The new standard will no impact on the Company's financial statements as the Company does not presently have any long-term lease commitments.

ii) AASB Interpretation 23 Uncertainty over Income Tax Treatments Interpretation 23 requires the assessment of whether the effect of uncertainty over income tax treatments should be included in the determination of taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates. The Interpretation outlines the requirements to determine whether an entity considers uncertain tax treatments separately, the assumptions an entity makes about the examination of tax treatments by taxation authorities, how an entity determines taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates and how an entity considers changes in facts and circumstances.

The Company has adopted Interpretation 23 from 1 July 2019, based on an assessment of whether it is 'probable' that a taxation authority will accept an uncertain tax treatment. There has been no impact from the adoption of Interpretation 23 in this reporting period.

b) New and revised Accounting Standards in issue but not yet effective

i) Other new and revised Accounting Standards

There are no other standards that are not yet effective that are expected to have a material impact on the company in the current or future reporting periods or on foreseeable future transactions.

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

Note 2: Financial Assets

	31 December 2019 \$	30 June 2019 \$
Non- Current	,	·
Financial assets carried at fair value		
through profit or loss		
Unlisted investments:		
Bio101group Pty Ltd	470,000	375,000
BioImpact Pty Ltd	100	100
BTC Speciality Health Pty Ltd	6,000,000	6,000,000
Total Non- Current Financial Assets	6,470,100	6,375,100

Fair value of financial instruments: Valuation techniques and assumptions applied for the purposes of measuring fair value

The fair values of unlisted investments are determined in accordance by directors' valuations, which are based on their experience in the industry. Directors have used assumptions, such as estimated cash flows, project plans and other market data available in determining their valuation of unlisted investments. Should these assumptions change in subsequent periods the fair value may be impacted and accounted for through the profit or loss. The directors have reviewed discounted cash flows and multiple of revenue and profit calculations to determine the fair value holding costs of the investments.

Name of Investment	Core Activity
Bio101group Pty Ltd	Finance and administration services to private, public and listed companies in the Australian life sciences sector. These services include accounting, company secretarial, taxation, grant applications, payroll administration, business development, royalty and partner management.
BioImpact Pty Ltd	Invests in and holds intellectual property rights for pharmaceuticals and medical devices for the development and commercialisation in the Asia/Pacific region. Technologies and products are sourced form a range of global third parties.
BTC Speciality Health Pty Ltd	Commercialises and distributes the BTC health group's in- licensed pharmaceuticals and medical devices in the Asia/Pacific region.

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2019

Note 2: Financial Assets (continued)

Fair value measurements recognised in the statement of financial position:

The following table provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which the fair value is observable.

- a) Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities.
- b) Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- c) Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

	Level 1	Level 2	Level 3	Total
31 December 2019	\$	\$	\$	\$
Financial assets Unlisted investments– Financial assets				
carried at fair value through profit or loss	-	-	6,470,100	6,470,100
	-	-	6,470,100	6,470,100
30 June 2019				
Financial assets Unlisted investments– Financial assets				
carried at fair value through profit or loss	-	-	6,375,100	6,375,100
	_	-	6,375,100	6,375,100

There were no transfers between levels during the year.

Note 3: Loans to investee companies

	31 December 2019 \$	30 June 2019 \$
Non- Current	•	•
Loans to investee companies		
BioImpact Pty Ltd	477,539	347,691
BTC Speciality Health Pty Ltd	1,050,467	890,000
Total Loans to investee companies	1,528,006	1,237,691

The loans issued to BioImpact Pty Ltd and BTC Speciality Health Pty Ltd are non-interest bearing and have no fixed terms of repayment.

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2019

Note 4: Issued Capital

	31 December 31 December 2019 2019		30 June 2019	30 June 2019
••	Shares	\$	Shares	\$
Movement Opening balance	244,542,783	53,104,855	130,296,532	44,255,057
Share Placement 22 May 2019 Capital raising costs			31,841,127	2,547,290 (90,707)
Share Placement 13 June 2019 Capital raising costs			14,871,250	1,189,700 (17,850)
Share Placement 27 June 2019 Capital raising costs			67,533,874	5,402,710 (181,345)
Share Placement 3 July 2019 Capital raising costs	625,000	50,000 (1,922)		
Share issue 27 August 2019 Share issue 2 December 2019	71,428 892,857	10,000 125,000		
Closing balance	246,132,068	53,287,933	244,542,783	53,104,855

Note 5: Contingent Liabilities

There were no material contingent liabilities of which the Company is aware of at the date of this report.

Note 6. Related party transactions

The Company's significant related parties remain as disclosed in note 16 of the 2019 Annual Report. There were no material differences in related parties or related party transactions in the period compared to the prior year.

Note 7: Subsequent Events

No material matters have arisen between the end of the half-year ended 31 December 2019 and the date of this report which in the opinion of the directors of the company, will affect significantly the operations of the entity, the results of those operations, or the state of the affairs of the entity, in subsequent financial years.

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2019

Note 8: Segment Information

Operating and reportable segments have been identified on the basis of internal reports of the company that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segments and to assess their performance. The chief operating decision maker has been identified as the Executive Chairman.

The company has single and reportable operating segment being investments in biotechnology and pharmaceutical ventures.

DIRECTORS' DECLARATION

The directors declare that:


- (a) in the directors' opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable; and
- (b) in the directors' opinion, the attached financial statements and notes thereto are in accordance with the Corporations Act 2001, including compliance with accounting standards and giving a true and fair view of the financial position and performance of the Company.

Signed in accordance with a resolution of the Board of Directors made pursuant to s.303(5) of the Corporations Act 2001.

On behalf of the directors,

Richard Treagus Executive Chairman

Dated 18th February 2020



Collins Square, Tower 5 727 Collins Street Melbourne VIC 3008

Correspondence to: GPO Box 4736 Melbourne VIC 3001

T+61 3 8320 2222 F+61 3 8320 2200 E info.vic@au.gt.com W www.grantthornton.com.au

Independent Auditor's Report

To the Members of BTC Health Limited

Report on the review of the half year financial report

Conclusion

We have reviewed the accompanying half year financial report of BTC Health Limited, which comprises the statement of financial position as at 31 December 2019, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the half year ended on that date, a description of accounting policies, other selected explanatory notes, and the directors' declaration.

Based on our review, which is not an audit, nothing has come to our attention that causes us to believe that the half year financial report of BTC Health Limited does not give a true and fair view of the financial position of the Company as at 31 December 2019, and of its financial performance and its cash flows for the half year ended on that date, in accordance with the *Corporations Act 2001*, including complying with Accounting Standard AASB 134 *Interim Financial Reporting*.

Directors' responsibility for the half year financial report


The Directors of the Company are responsible for the preparation of the half year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the Directors determine is necessary to enable the preparation of the half year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express a conclusion on the half year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half year financial report is not in accordance with the Corporations Act 2001 including giving a true and fair view of the Company's financial position as at 31 December 2019 and its performance for the half year ended on that date, and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001. As the auditor of BTC Health Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389 www.grantthornton.com.au

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.



A review of a half year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the Corporations Act 2001.

Grant Thornton Audit Pty Ltd Chartered Accountants

anat Thompson

M A Cunningham

Partner - Audit & Assurance

Melbourne, 18 February 2020